Lead Sponsor

Polish Lymphoma Research Group

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically confirmed:
•Follicular lymphoma grade 1, 2, 3a
•Marginal zone lymphoma, including MALT type
•Small lymphocytic lymphoma (BM inv. \< 30%)
•Lymphoplasmacytic lymphoma
•Clinical stage II-IV (Ann Arbor). Stage I is allowed if bulky (Ø \> 7 cm) or if radiotherapy is not appropriate in judgment of treating physician
•Measurable lesion(s) in at least one site
•Patients previously untreated
•Patients presenting with symptoms requiring treatment:
•Progressive disease
•Symptoms related to tumor bulk
•Cytopenias related to bone marrow and/or spleen involvement B symptoms
•Age ≥ 18 years
•Performance status \</=2
•Written informed consent

•Grade 3b FL
•Transformed lymphoma
•CNS involvement
•Patient taking steroids for \> 2 weeks during last 4 weeks at a dose equivalent to ≥ 20 mg prednisone
•Other malignancy
•Major surgery within 4 weeks
•Hb \< 8 g/dl, ANC \< 1.5 x 109/L, Plt \<100 109/L unless due to lymphoma
•Impairment of renal function (creatinine \> 1.5 x UNV) or liver function (total bilirubin 1.5 x UNV, SGOT \> 2.5 x UNV not due to lymphoma
•Known infection, with HBV, HCV (acute \< 6 mos. or chronic hepatitis) or HIV
•Serious underlying medical conditions
•Life expectancy \< 6 months
•Known allergy to murine protein

Related studies

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

NCT06191744 · Follicular Lymphoma (FL)

NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more

NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.